Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

anges in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.

The third study in the Phase 3 program, a multi-center safety study, for which patient recruitment was completed in December 2008, is an ongoing open-label, single-armed study involving 529 patients in North America. The lead investigator is Joel Kaufman, M.D., Associate Clinical Professor in Urology at University of Colorado School of Medicine in Denver, Colorado and at Urology Research Options in Aurora, Colorado.

First efficacy results are expected during the third quarter of 2009 with an NDA filing targeted in 2010.

About Cetrorelix

Cetrorelix pamoate is an investigational agent that has shown in Phase 2 studies to provide fast and long lasting relief of BPH symptoms and was well tolerated, with a low incidence of sexual side effects. Cetrorelix is part of AEterna Zentaris' luteinizing hormone-releasing hormone (LHRH) antagonist therapeutic approach. This peptide-based active substance was developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovulation stimulation/assisted reproductive technologies) in Europe, the USA and Japan. It was launched on the market through Serono (now Merck Serono) in the U.S., Europe and in several other countries, as well as in Japan through Shionogi.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men - affecting more than 20 million men in the United States - but its etiology is far from being completely understood. Data from ongoing research suggest BPH and lower uri
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Reston, VA (PRWEB) July 28, 2014 ... leading nonprofit authority on the use of health IT ... its Health Plan Identifier (HPID) Workgroup has ... Between a Health Plan and Payer?” The HPID Workgroup, ... worked closely with the Centers for Medicare and Medicaid ...
(Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
(Date:7/28/2014)... Hershey, PA & Boston, MA (PRWEB) July 28, 2014 ... into collaboration agreements with two researchers to further develop ... and deadly malignant brain tumor, in combination with their ... executed by ITI and Duke University, are based on ... MHSc, Chief, Division of Neurosurgery at The Preston Robert ...
(Date:7/28/2014)... The global market for biotechnology is expected ... a new study by Grand View Research, Inc. Increasing ... vaccines and drugs in an attempt to improve healthcare ... to drive market demand over the next six years. ... the use of genetically engineered seeds is expected to ...
Breaking Biology Technology:WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... March 14, 2011 Argentum Medical, LLC today issued a ... versus Noble Biomaterials, Inc. "The most important thing ... patents and it is business as usual for Argentum," said ... case concerned non-patent issues and is currently being appealed. We ...
... Biofuels, a bioenergy crop company using breeding and biotechnology ... it is applying more than 1.6 million genetic markers ... of marker assisted selection (MAS) methods to produce elite, ... the announcement during its presentation at the Biowise 2011 ...
... March 11, 2011 /PRNewswire-Asia-FirstCall/ --Tianyin Pharmaceutical Co., Inc. (NYSE ... specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, ... at the 23rd ROTH Annual OC Growth Stock Conference ... Carlton in Dana Point, California. Dr. James ...
Cached Biology Technology:Argentum Medical Issues Response to Recent Decision in Litigation With Noble Biomaterials 2SG Biofuels Advances Jatropha Biotech Platform with Application of Genetic Markers to Reference Genome 2TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011 2
(Date:7/28/2014)... Roald Amundsen became the first man to reach the ... years later, an international team of scientists led by ... proven that air pollution from industrial activities arrived long ... from widely spaced locations around the Antarctic continent, including ... and precise reconstruction to date of lead pollution over ...
(Date:7/27/2014)... asteroid strike that wiped them out if it had ... say. , A fresh study using up-to-date fossil records ... a new narrative of the prehistoric creatures, demise, some ... the few million years before a 10km-wide asteroid struck ... This included extensive volcanic activity, changing sea levels and ...
(Date:7/27/2014)... discovered a new species of mayfly in the southern Western ... In fact, this is the first time that any mayfly ... in peninsular India. , The new species, called Labiobaetis ... for his substantial contribution to the understanding of the Ephemeroptera ... a study that describes the new mayfly in the ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Dinosaurs fell victim to perfect storm of events, study shows 2
... by researchers at Baylor College of Medicine (BCM) and ... DNA sequencing to the patient's bedside, the doctor's office ... battlefield. , "We could eventually do direct detection of ... performed in the laboratory, said Dr. Michael L. Metzker, ...
... in the March 30th edition of the prestigious scientific journal ... UK's national academy of science) shows that the transfer of ... is much larger and more extensive than previously believed. , ... in a contentious debate. It is the first to isolate ...
... "A Method of Reconstituting Nucleic Acid Molecules" today to ... of DermaPlus, Inc. The patent covers methods for recovering ... allow scientists to reassemble everything from prehistoric, extinct animals ... applied by our scientists, brings us closer to our ...
Cached Biology News:Color-blind method opens new doors in DNA sequencing 2Color-blind method opens new doors in DNA sequencing 3Researchers reveal the infectious impact of salmon farms on wild salmon 2Researchers reveal the infectious impact of salmon farms on wild salmon 3Researchers reveal the infectious impact of salmon farms on wild salmon 4Dinosaur DNA? New Patent Covers Degraded DNA recovery 2
Troponin I (22B11)...
... low temperature freezers offer a superior ... of biological samples with high capacities. ... inner doors ensure excellent warming protection ... ,Application oriented accessories simplify tracking of ...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
Thermo Labsystems offers a basic reader for 96-well microplates that is especially adapted for ELISA and other colorimetric assays....
Biology Products: